Day |
Time* |
Session
Type |
Session Name |
Location |
# of
Abstracts |
Sat |
9:30a |
Oral |
Education Session
(3 presentations; no abstracts available) |
Theater AB |
3 |
Sat |
2:30p |
Oral |
Scientific Program |
293-296 |
3 |
Sat |
5:30p |
Poster |
322. Disorders of Coagulation or Fibrinolysis: Poster I |
Hall E |
1 |
Sat |
5:30p |
Poster |
601. Chromosomal Rearrangements and DNA Repair: Poster I |
Hall E |
2 |
Sat |
5:30p |
Poster |
613. Acute Myeloid Leukemia: Pathophysiology & Clinical Studies: Poster I |
Hall E |
1 |
Sat |
5:30p |
Poster |
802. Chemical Biology and Experimental Therapeutics: Poster I |
Hall E |
2 |
Sat |
5:30p |
Poster |
901. Health Services and Outcomes Research: Poster I |
Hall E |
8 |
Sat |
5:30p |
Poster |
651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I |
Hall G |
70 |
Sat |
5:30p |
Poster |
652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I |
Hall G |
14 |
Sat |
5:30p |
Poster |
653. Myeloma: Therapy, excluding Transplantation: Poster I |
Hall G |
59 |
Sat |
5:30p |
Poster |
702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster I |
Hall G |
1 |
Sat |
5:30p |
Poster |
711. Cell Collection and Processing: Poster I |
Hall G |
2 |
Sat |
5:30p |
Poster |
723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Poster I |
Hall G |
1 |
Sat |
5:30p |
Poster |
731. Clinical Allogeneic and Autologous Transplantation - Results: Poster I |
Hall G |
14 |
Sun |
7:30a |
Oral |
Scientific Program |
293-296 |
3 |
Sun |
9:30a |
Oral |
Education Session
(3 presentations; no abstracts available) |
Theater AB |
3 |
Sun |
2:55p |
Oral |
Plenary Session |
Hall F |
1 |
Sun |
5:15p |
Oral |
203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections: NK Cell Biology |
395-396 |
1 |
Sun |
5:00p |
Oral |
651. Myeloma: Biology and Pathophysiology, excluding Therapy: Predictive Markers of Myeloma Biology |
388-390 |
6 |
Sun |
5:00p |
Oral |
652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Signaling and Microenvironment |
391-392 |
6 |
Sun |
5:00p |
Oral |
703. Adoptive Immunotherapy: Novel T cell Therapies |
393-394 |
3 |
Sun |
5:00p |
Oral |
723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Relapse after Transplantation - Novel Strategies |
R06-R07 |
2 |
Sun |
5:15p |
Oral |
731. Clinical Allogeneic and Autologous Transplantation - Results: Haploidentical and Umbilical Cord Blood Transplantation |
208-210 |
1 |
Sun |
6:30p |
Poster |
603. Oncogenes and Tumor Suppressors: Poster II |
Hall E |
1 |
Sun |
6:30p |
Poster |
604. Molecular Pharmacology, Drug Resistance: Poster II |
Hall E |
1 |
Sun |
6:30p |
Poster |
802. Chemical Biology and Experimental Therapeutics: Poster II |
Hall E |
|
Sun |
6:30p |
Poster |
901. Health Services and Outcomes Research: Poster II |
Hall E |
9 |
Sun |
6:30p |
Poster |
651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II |
Hall G |
70 |
Sun |
6:30p |
Poster |
652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II |
Hall G |
15 |
Sun |
6:30p |
Poster |
653. Myeloma: Therapy, excluding Transplantation: Poster II |
Hall G |
57 |
Sun |
6:30p |
Poster |
702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster II |
Hall G |
1 |
Sun |
6:30p |
Poster |
711. Cell Collection and Processing: Poster II |
Hall G |
1 |
Sun |
6:30p |
Poster |
723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Poster II |
Hall G |
3 |
Sun |
6:30p |
Poster |
731. Clinical Allogeneic and Autologous Transplantation - Results: Poster II |
Hall G |
21 |
Mon |
7:15a |
Oral |
611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Genomic Alterations in Acute Lymphoblastic Leukemia--Implications for Pathogenesis, Prognosis and Therapy |
291-292 |
1 |
Mon |
7:00a |
Oral |
651. Myeloma: Biology and Pathophysiology, excluding Therapy: Novel Biological Targets |
388-390 |
5 |
Mon |
7:00a |
Oral |
652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Drug Resistance |
391-392 |
6 |
Mon |
7:00a |
Oral |
653. Myeloma: Therapy, excluding Transplantation: Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma |
393-394 |
5 |
Mon |
10:30a |
Oral |
651. Myeloma: Biology and Pathophysiology, excluding Therapy: Clonal Evolution and Genomic Heterogeneity in Myeloma |
388-390 |
6 |
Mon |
10:30a |
Oral |
653. Myeloma: Therapy, excluding Transplantation I |
393-394 |
6 |
Mon |
10:45a |
Oral |
731. Clinical Allogeneic and Autologous Transplantation - Results: Autologous Transplantation for Lymphoma, Myeloma and APL |
208-210 |
2 |
Mon |
2:45p |
Oral |
651. Myeloma: Biology and Pathophysiology, excluding Therapy: Genomics |
388-390 |
6 |
Mon |
3:00p |
Oral |
624. Lymphoma: Therapy with Biological Agents, Excluding Pre-Clinical Models: Immunotherapy for Indolent Lymphomas |
Ballroom AB |
1 |
Mon |
2:45p |
Oral |
653. Myeloma: Therapy, excluding Transplantation: Treatment Options for Newly Diagnosed Multiple Myeloma Patients |
393-394 |
6 |
Mon |
3:00p |
Oral |
731. Clinical Allogeneic and Autologous Transplantation - Results: Optimizing Outcomes After Transplantation - Selecting Patients, Donor and Transplant Strategies |
208-210 |
1 |
Mon |
5:30p |
Oral |
602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Epigenetics of Hematopoiesis and Leukemia |
395-396 |
1 |
Mon |
4:30p |
Oral |
604. Molecular Pharmacology, Drug Resistance: Environmental Implications in Leukemia Therapy and Molecular Mechanisms of Drug Resistance and Novel Biomarkers in Hematologic Malignances |
275-277 |
2 |
Mon |
4:30p |
Oral |
651. Myeloma: Biology and Pathophysiology, excluding Therapy: Bone Marrow Microenvironment and Myeloma |
388-390 |
6 |
Mon |
4:30p |
Oral |
653. Myeloma: Therapy, excluding Transplantation II |
393-394 |
6 |
Mon |
5:00p |
Oral |
901. Health Services and Outcomes Research: Malignant Hematology and Stem Cell Transplantation |
391-392 |
1 |
Mon |
5:00p |
Oral |
611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis I |
291-292 |
1 |
Mon |
7:15p |
Oral |
611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis I |
291-292 |
1 |
Mon |
6:15p |
Oral |
651. Myeloma: Biology and Pathophysiology, excluding Therapy: Microenvironment |
388-390 |
6 |
Mon |
6:30p |
Oral |
653. Myeloma: Therapy, excluding Transplantation: Advances in Multiple Myeloma and Plasma Cell Leukemia |
393-394 |
5 |
Mon |
6:15p |
Oral |
731. Clinical Allogeneic and Autologous Transplantation - Results: Evidence-based Decision Making II - Transplantation for Lymphoma and Plasma Cell Disorders |
208-210 |
4 |
Mon |
6:00p |
Poster |
203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections: Poster III |
Hall E |
2 |
Mon |
6:00p |
Poster |
331. Pathophysiology of Thrombosis: Poster III |
Hall E |
1 |
Mon |
6:00p |
Poster |
601. Chromosomal Rearrangements and DNA Repair: Poster III |
Hall E |
1 |
Mon |
6:00p |
Poster |
602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster III |
Hall E |
2 |
Mon |
6:00p |
Poster |
604. Molecular Pharmacology, Drug Resistance: Poster III |
Hall E |
4 |
Mon |
6:00p |
Poster |
661. Malignant Stem and Progenitor Cells: Poster III |
Hall E |
1 |
Mon |
6:00p |
Poster |
801. Gene Therapy and Transfer: Poster III |
Hall E |
1 |
Mon |
6:00p |
Poster |
802. Chemical Biology and Experimental Therapeutics: Poster III |
Hall E |
4 |
Mon |
6:00p |
Poster |
623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster III |
Hall G |
1 |
Mon |
6:00p |
Poster |
652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster III |
Hall G |
27 |
Mon |
6:00p |
Poster |
703. Adoptive Immunotherapy: Poster III |
Hall G |
1 |
Mon |
6:00p |
Poster |
711. Cell Collection and Processing: Poster III |
Hall G |
3 |
Mon |
6:00p |
Poster |
722. Clinical Allogeneic Transplantation - Acute and Chronic GVHD, Immune Reconstitution: Poster III |
Hall G |
1 |
Mon |
6:00p |
Poster |
723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Poster III |
Hall G |
1 |
Tue |
8:15a |
Oral |
601. Chromosomal Rearrangements and DNA Repair |
220-222 |
1 |
Tue |
7:45a |
Oral |
614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Standard Therapies and Novel Targets For All Ages |
Ballroom C |
1 |
Tue |
7:30a |
Oral |
652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Drugs |
295-296 |
6 |
Tue |
8:00a |
Oral |
703. Adoptive Immunotherapy: Optimizing Cellular Therapy |
393-394 |
1 |
Tue |
8:15a |
Oral |
711. Cell Collection and Processing II |
R02-R03 |
3 |
Tue |
7:45a |
Oral |
723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Late Complications |
R06-R07 |
1 |
Tue |
7:45a |
Oral |
731. Clinical Allogeneic and Autologous Transplantation - Results: Allogeneic Transplantation |
208-210 |
1 |
Tue |
8:30a |
Oral |
802. Chemical Biology and Experimental Therapeutics: New Experimental Therapeutic Approaches to Benign and Malignant Hematology |
R04-R05 |
1 |
What is the status of Elotuzumab? I don't see any abstracts discussing it.
Hi Pete - We don't think anything is amiss with elotuzumab. There just aren't any presentations about it this year at ASH.
However, we're looking into it, and we'll let you know what we find out.
Thanks for the question.
To Myeloma Beacon Staff:
Thanks for checking on that.
On a different topic: daratumumab had been designated by the FDA with 'fast track status' back in April 2013:
http://www.myelomabeacon.com/news/2013/04/08/beacon-newsflashes-april-8-2013/
What is your sense, based on the ASH 2013 abstracts, that daratumumab will be approved in the next 6-9 month? I understand that your reply (if any) would be highly speculative. But you folks might have a better feel for this than a layperson like me.
Thank you.
Pete
Hi how can I order abstracts on the Myeloma presentations
Progress toward fundraising goal
for all of 2020:
15%
For more information, see the Beacon's
"2020 Fundraising: Goals And Updates" page